". "Ergolines experiment". "HPCWire:Sugon Announces Completion of Datacenter in Europe". "InsideHPC: Sugon Moves HPC as a ...
SKF-83,959 Ergolines: Bromocriptine • Cabergoline • Dihydroergocryptine • Lisuride • Lysergic acid diethylamide (LSD) • ...
... causes arterial/arteriolar vasodilation leading to a decrease in blood pressure by activating peripheral D1 receptors.[5] It decreases afterload and also promotes sodium excretion via specific dopamine receptors along the nephron. The renal effect of fenoldopam and dopamine may involve physiological antagonism of the renin-angiotensin system in the kidney.[6] In contrast to dopamine, fenoldopam is a selective D1 receptor agonist with no effect on beta adrenoceptors, although there is evidence that it may have some alpha-1 [7] and alpha-2 adrenoceptor antagonist activity.[5] D1 receptor stimulation activates adenylyl cyclase and raises intracellular cyclic AMP, resulting in vasodilation of most arterial beds, including renal, mesenteric, and coronary arteries.[8] to cause a reduction in systemic vascular resistance. Fenoldopam has a rapid onset of action (4 minutes) and short duration of action (, 10 minutes) and a linear dose-response relationship at usual clinical doses.[9] ...
Ergolines (e.g., ALD-52, cabergoline, dihydroergotamine, ergine (LSA), ergotamine, lisuride, LA-SS-Az, LSB, LSD, LSD-Pip, LSH, ... Ergolines (e.g., 1P-LSD, ALD-52, bromocriptine, cabergoline, ergine (LSA), ergometrine (ergonovine), ergotamine, lisuride, LA- ... Ergolines (e.g., 2-Br-LSD (BOL-148), amesergide, bromocriptine, cabergoline, dihydroergotamine, ergotamine, LY-53857, LY- ... Agonists: Ergolines (e.g., dihydroergocryptine, dihydroergotamine, ergotamine, lisuride, LSD, mesulergine, metergoline, ...
The hormone prolactin stimulates lactation (production of breast milk). Dopamine, released by the hypothalamus stops the release of prolactin from the pituitary gland. Domperidone, by acting as an anti-dopaminergic agent, results in increased prolactin secretion, and thus promotes lactation (that is, it is a galactogogue). In some nations, including Australia, domperidone is used off-label, based on uncertain and anecdotal evidence of its usefulness, as a therapy for mothers who are having difficulty breastfeeding.[24][25] In the United States, domperidone is not approved for this or any other use.[26][27] A study called the EMPOWER trial was designed to assess the effectiveness and safety of domperidone in assisting mothers of preterm babies to supply breast milk for their infants.[28] The study randomized 90 mothers of preterm babies to receive either domperidone 10 mg orally three times daily for 28 days (Group A) or placebo 10 mg orally three times daily for 14 days followed by domperidone ...
Ergolines (e.g., ALD-52, cabergoline, dihydroergotamine, ergine (LSA), ergotamine, lisuride, LA-SS-Az, LSB, LSD, LSD-Pip, LSH, ... Ergolines (e.g., 1P-LSD, ALD-52, bromocriptine, cabergoline, ergine (LSA), ergometrine (ergonovine), ergotamine, lisuride, LA- ... Ergolines (e.g., 2-Br-LSD (BOL-148), amesergide, bromocriptine, cabergoline, dihydroergotamine, ergotamine, LY-53857, LY- ... Agonists: Ergolines (e.g., dihydroergocryptine, dihydroergotamine, ergotamine, lisuride, LSD, mesulergine, metergoline, ...
Djaldetti Ruth; Giladi Nir; Hassin-Baer Sharon; Shabtai Hertzel; Melamed Eldad (November-December 2003). "Pharmacokinetics of Etilevodopa Compared to Levodopa in Patient's With Parkinson's Disease: An Open-label, Randomized, Crossover Study". Clinical Neuropharmacology. 26 (6): 322-326. doi:10.1097/00002826-200311000-00012. PMID 14646613 ...
Melis MR, Succu S, Sanna F, Melis T, Mascia MS, Enguehard-Gueiffier C, Hubner H, Gmeiner P, Gueiffier A, Argiolas A (October 2006). "PIP3EA and PD-168077, two selective dopamine D4 receptor agonists, induce penile erection in male rats: site and mechanism of action in the brain". The European Journal of Neuroscience. 24 (7): 2021-30. doi:10.1111/j.1460-9568.2006.05043.x. PMID 17067298 ...
The present meta-analysis was conducted to estimate the magnitude of the effects of methylphenidate and amphetamine on cognitive functions central to academic and occupational functioning, including inhibitory control, working memory, short-term episodic memory, and delayed episodic memory. In addition, we examined the evidence for publication bias. Forty-eight studies (total of 1,409 participants) were included in the analyses. We found evidence for small but significant stimulant enhancement effects on inhibitory control and short-term episodic memory. Small effects on working memory reached significance, based on one of our two analytical approaches. Effects on delayed episodic memory were medium in size. However, because the effects on long-term and working memory were qualified by evidence for publication bias, we conclude that the effect of amphetamine and methylphenidate on the examined facets of healthy cognition is probably modest overall. In some situations, a small advantage may be ...
Ergolines (e.g., ALD-52, cabergoline, dihydroergotamine, ergine (LSA), ergotamine, lisuride, LA-SS-Az, LSB, LSD, LSD-Pip, LSH, ... Ergolines (e.g., 1P-LSD, ALD-52, bromocriptine, cabergoline, ergine (LSA), ergometrine (ergonovine), ergotamine, lisuride, LA- ... Ergolines (e.g., 2-Br-LSD (BOL-148), amesergide, bromocriptine, cabergoline, dihydroergotamine, ergotamine, LY-53857, LY- ... Metergoline is a psychoactive drug of the ergoline chemical class which acts as a ligand for various serotonin and dopamine ...
Ergolines (e.g., ergotamine, dihydroergotamine, lisuride, terguride). *Etoperidone. *Eugenodilol. *Fenspiride. *Hydroxyzine. * ...
... is a synthetic compound that acts as a selective antagonist on D2 dopamine receptors.[1] Its selectivity to the cerebral D2 receptors is characterized by its respective Ki-values, which are as follows: 1.8, 3.5, 2400 and 18000 nM for D2, D3, D4 and D1 receptors respectively. It can be radiolabelled with radioisotopes, e.g. 3H or 11C and used as a tracer for in vitro imaging (autoradiography) as well as in vivo imaging positron emission tomography (PET). Images obtained by cerebral PET scanning (e.g. PET/CT or PET/MRI) allow the non-invasive assessment of the binding capacity of the cerebral D2 dopamine receptor, which can be useful for the diagnosis of movement disorders. In particular, cerebral D2 receptor binding as measured by carbon-11-raclopride (11C-raclopride) has shown to reflect disease severity of Huntington's disease, a genetical disease characterized by selective degeneration of cerebral D2 receptors.[2] Other studies have investigated the relationship of D2 receptor ...
In 1960 the Austrian biochemist Oleh Hornykiewicz, while at the University of Vienna, examined results of autopsies of patients who had died with Parkinson's disease. He suggested that the disease was associated with, or caused by, a reduction in the levels of dopamine in the basal ganglia of the brain. Since dopamine itself did not enter the brain, he tried treating twenty patients with a racemic mixture of dihydroxyphenylalanine (DOPA), which could enter the brain and be converted there to dopamine by the action of DOPA decarboxylase. His results were positive, as were those of another trial in Montreal run by André Barbeau. Unfortunately, other investigators were unable to replicate these early results, and the use of DOPA remained in question until 1967, when George Cotzias at the Brookhaven National Laboratories in Upton, New York, used megadoses of DOPA, up to 16 grams per day. Not long after these results became known, Curt Porter at Merck showed that L-DOPA was the active stereoisomer, ...
InChI=1S/C20H33N3O3S/c1-4-10-22-14-17(21-27(25,26)23(5-2)6-3)11-16-12-18-15(13-19(16)22)8-7-9-20(18)24/h7-9,16-17,19,21,24H,4-6,10-14H2,1-3H3/t16-,17+,19-/m1/s1 ...
... crosses the protective blood-brain barrier, whereas dopamine itself cannot. Thus, L-DOPA is used to increase dopamine concentrations in the treatment of Parkinson's disease and dopamine-responsive dystonia. This treatment was made practical and proven clinically by George Cotzias and his coworkers, for which they won the 1969 Lasker Prize.[4][5] Once L-DOPA has entered the central nervous system, it is converted into dopamine by the enzyme aromatic L-amino acid decarboxylase, also known as DOPA decarboxylase. Pyridoxal phosphate (vitamin B6) is a required cofactor in this reaction, and may occasionally be administered along with L-DOPA, usually in the form of pyridoxine.. Besides the central nervous system, L-DOPA is also converted into dopamine from within the peripheral nervous system. Excessive peripheral dopamine signaling causes many of the adverse side effects seen with sole L-DOPA administration. To bypass these effects, it is standard clinical practice to coadminister (with ...
Ergolines can antagonise the effects of molsidomine. Molsidomine belongs to the drug class of nitrovasodilators. It releases NO ...
LSD is an ergoline derivative. It is commonly synthesized by reacting diethylamine with an activated form of lysergic acid. ... the precursor to all biosynthetic ergoline compounds. However, LSD and iso-LSD, the two C-8 isomers, rapidly interconvert in ...
This location was setting for ad campaigns and works for i.e. Mercedes-Benz, Porsche, Ergoline, or Bugatti. In 2012 Rieker sold ...
... is an ergoline fungal isolate. Festuclavine dehydrogenase Wallwey, C; Matuschek, M; Xie, XL; Li, SM (2010). "Ergot ...
Unlike many other ergolines, such as ergotamine, nicergoline is not associated with cardiac fibrosis. It is used for vascular ... Moretti A, Carfagna N, Caccia C, Carpentieri M (1988). "Effect of ergolines on neurotransmitter systems in the rat brain". Arch ... However, only a subset of ergolines are associated with fibrosis and evidence suggests that nicergoline does not carry fibrotic ... risk like other ergoline derivatives such as ergotamine. Nicergoline is considered unsafe in porphyria. The side effects of ...
... is an ergoline alkaloid. It is a potent, selective, anticancer compound, with in vitro activity ...
Chemically, CPA is related to ergoline alkaloids. CPA was originally isolated from Penicillium cyclopium and subsequently from ...
... is an ergot alkaloid (ergoline alkaloid). It can be produced from C. fusiformis from Pennisetum typhoideum. It is ... "Clavicipitaceous fungi associated with ergoline alkaloid-containing convolvulaceae". J. Nat. Prod. 70 (12): 1955-1960. doi: ...
... (INN), also known as 2-bromolisuride, is an antidopaminergic and serotonergic agent of the ergoline group which ... It was the first antidopaminergic ergoline derivative to be discovered. The pharmacodynamic actions of bromerguride are said to ... Löschmann PA, Horowski R, Wachtel H (1992). "Bromerguride--an ergoline derivative with atypical neuroleptic properties". Clin ...
Further reactions, involving methyltransferase and oxygenase enzymes, yield the ergoline, lysergic acid. Lysergic acid (LA) is ... it is structurally and biochemically closely related to ergoline. It possesses structural similarity to several ...
... is a dopamine agonist of the non-ergoline class. Pramipexole was approved for medical use in the United States in ...
... is an ergoline compound made by certain fungi. Both 8α and 8β diastereomers (epimers) were named fumigaclavine ...
... is an ergoline fungal isolate, chemically related to festuclavine. "PubCHEM Open Chemistry Database". NCBI. ...
The ergoline antimigraine agent ergotamine also acts on this receptor. Serenics such as batoprazine, eltoprazine, and ...
Ergine Ergoline Lysergamides Lysergic acid diethylamide (LSD) Brown, H. C.; et al. (1955). Braude, E. A.; Nachod, F. C. (eds ... Lysergic acid, also known as D-lysergic acid and (+)-lysergic acid, is a precursor for a wide range of ergoline alkaloids that ...